Atezolizumab addition to platinum doublet: evaluating survival outcomes for patients with extensive disease small cell lung cancer

被引：2

作者：

Kubo, Sousuke ^{[1
]}

Kobayashi, Nobuaki ^{[1
]}

Matsumoto, Hiromi ^{[1
]}

Somekawa, Kohei ^{[1
]}

Kaneko, Ayami ^{[1
]}

Hashimoto, Hisashi ^{[1
]}

Teranishi, Shuhei ^{[2
]}

Watanabe, Keisuke ^{[1
]}

Horita, Nobuyuki ^{[1
]}

Hara, Yu ^{[1
]}

Kudo, Makoto ^{[2
]}

Kaneko, Takeshi ^{[1
]}

机构：

[1] Yokohama City Univ, Grad Sch Med, Dept Pulmonol, Fukuura 3-9,Kanazawa Ku, Yokohama, Kanagawa 2360004, Japan

[2] Yokohama City Univ, Resp Dis Ctr, Med Ctr, 4-59 Urafune Cho,Minami Ku, Yokohama, Japan

来源：

JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY | 2023年 / 149卷 / 19期

关键词：

Extensive disease small cell lung cancer (ED-SCLC); Atezolizumab; Carboplatin and etoposide (EP); Overall survival (OS); Immune checkpoint inhibitors (ICIs); Real-world efficacy; C-REACTIVE PROTEIN; NSCLC PATIENTS; IMMUNOTHERAPY; ASSOCIATION;

D O I：

10.1007/s00432-023-05457-9

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

BackgroundThe efficacy of adding atezolizumab to the platinum doublet regimen for extensive disease small cell lung cancer (ED-SCLC) remains marginally limited.MethodsWe retrospectively assessed the real-world efficacy and safety of atezolizumab in addition to carboplatin and etoposide (EP + A), versus carboplatin and etoposide (EP) alone in previously untreated ED-SCLC patients.ResultsFrom a total of 99 patients, 46 were assigned to the EP + A group, and 53 to the EP group. No significant difference was observed in progression-free survival between the groups. However, the overall survival (OS) was significantly longer in the EP + A group (20.8 vs 12.1 months; HR: 0.52; p = 0.0127). Patients older than 70 years, male, with performance status 0-1, without liver metastasis, and low levels of C-reactive protein and neutrophil-lymphocyte ratio, experienced longer OS in the EP + A group compared to the EP group.ConclusionThe addition of atezolizumab to the platinum doublet regimen significantly extended OS in ED-SCLC patients, particularly among certain subgroups, suggesting its potential value in personalized treatment strategies. Further investigation is warranted to validate these findings.

引用

页码：17419 / 17426

页数：8

共 25 条

[1] Small Cell Lung Cancer: Where Do We Go From Here? [J].

Byers, Lauren Averett ;

Rudin, Charles M. .

CANCER, 2015, 121 (05) :664-672

[2]

Chen ZQ., 2022, FRONT IMMUNOL, V8, P13

[3] Twenty years of phase III trials for patients with extensive-stage small-cell lung cancer: Perceptible progress [J].

Chute, JP ;

Chen, T ;

Feigal, E ;

Simon, R ;

Johnson, BE .

JOURNAL OF CLINICAL ONCOLOGY, 1999, 17 (06) :1794-1801

[4] Neutrophil to lymphocyte ratio and cancer prognosis: an umbrella review of systematic reviews and meta-analyses of observational studies [J].

Cupp, Meghan A. ;

Cariolou, Margarita ;

Tzoulaki, Ioanna ;

Aune, Dagfinn ;

Evangelou, Evangelos ;

Berlanga-Taylor, Antonio J. .

BMC MEDICINE, 2020, 18 (01)

[5] Cost effectiveness of immune checkpoint inhibitors for treatment of non-small cell lung cancer: A systematic review [J].

Ding, Haiying ;

Xin, Wenxiu ;

Tong, Yinghui ;

Sun, Jiao ;

Xu, Gaoqi ;

Ye, Ziqi ;

Rao, Yuefeng .

PLOS ONE, 2020, 15 (09)

[6] The prognostic impact of tumor mutational burden (TMB) in the first-line management of advanced non-oncogene addicted non-small-cell lung cancer (NSCLC): a systematic review and meta-analysis of randomized controlled trials [J].

Galvano, A. ;

Gristina, V ;

Malapelle, U. ;

Pisapia, P. ;

Pepe, F. ;

Barraco, N. ;

Castiglia, M. ;

Perez, A. ;

Rolfo, C. ;

Troncone, G. ;

Russo, A. ;

Bazan, V .

ESMO OPEN, 2021, 6 (03)

[7] Comparison of oral etoposide and standard intravenous multidrug chemotherapy for small-cell lung cancer: A stopped multicentre randomised trial [J].

Girling, DJ ;

Thatcher, N ;

Clark, PI ;

Hopwood, P ;

Twiddy, S ;

Stephens, RJ ;

Bailey, AJ ;

Machin, D ;

Bleehen, NM ;

Bolger, JJ ;

Connolly, CK ;

Hasleton, PS ;

Macbeth, FR ;

Moghissi, K ;

Saunders, MI ;

White, RJ ;

Alcock, S ;

Burt, H ;

Crossley, E ;

Decker, E ;

English, J ;

Foster, G ;

Hannigan, K ;

Heron, D ;

Hutchinson, J ;

Lomax, L ;

Mercer, V ;

Page, S ;

Rothwell, T ;

Staines, K ;

TaylorNeal, P ;

Turnball, V ;

Axford, AT ;

Earl, HM ;

Glaholm, J ;

Falk, SJ ;

Graham, JD ;

Jones, DK ;

Coombes, RC ;

Epstein, RJ ;

Hanham, I ;

Lowdell, CP ;

Newlands, E ;

Smith, DB ;

Cookson, JB ;

Anderson, H ;

Gribbin, HR ;

Sinclair, DJM ;

Carmichael, J ;

Chan, SYT .

LANCET, 1996, 348 (9027) :563-566

[8] Elevated Serum C-Reactive Protein as a Prognostic Marker in Small Cell Lung Cancer [J].

Hong, Soojung ;

Kang, Young Ae ;

Cho, Byoung Chul ;

Kim, Dae Joon .

YONSEI MEDICAL JOURNAL, 2012, 53 (01) :111-117

[9] First-Line Atezolizumab plus Chemotherapy in Extensive-Stage Small-Cell Lung Cancer [J].

Horn, L. ;

Mansfield, A. S. ;

Szczesna, A. ;

Havel, L. ;

Krzakowski, M. ;

Hochmair, M. J. ;

Huemer, F. ;

Losonczy, G. ;

Johnson, M. L. ;

Nishio, M. ;

Reck, M. ;

Mok, T. ;

Lam, S. ;

Shames, D. S. ;

Liu, J. ;

Ding, B. ;

Lopez-Chavez, A. ;

Kabbinavar, F. ;

Lin, W. ;

Sandler, A. ;

Liu, S. V. .

NEW ENGLAND JOURNAL OF MEDICINE, 2018, 379 (23) :2220-2229

[10] Efficacy and Prognostic Factors of Immune Checkpoint Inhibitors in the Treatment of Advanced Non-small Cell Lung Cancer [J].

Hu, Yu-xiong ;

Guo, Li-jing ;

Lin, Meng-qing ;

Lin, Qing-yu .

AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, 2023, 46 (04) :161-166

← 1 2 3 →